Cibc World Market Inc. Purchases New Shares in Moderna, Inc. $MRNA

Cibc World Market Inc. purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 16,797 shares of the company’s stock, valued at approximately $1,176,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Moderna by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock valued at $1,226,335,000 after buying an additional 399,487 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Moderna during the second quarter worth about $2,142,877,000. Capital World Investors purchased a new stake in shares of Moderna during the fourth quarter worth about $378,299,000. Invesco Ltd. lifted its stake in shares of Moderna by 15.7% in the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after acquiring an additional 1,115,131 shares in the last quarter. Finally, Theleme Partners LLP lifted its stake in shares of Moderna by 8.6% in the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock worth $217,100,000 after acquiring an additional 626,420 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on MRNA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Royal Bank Of Canada restated a “sector perform” rating and set a $130.00 price objective on shares of Moderna in a report on Wednesday, August 19th. William Blair raised Moderna from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 19th. Wolfe Research upgraded Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $74.31.

Moderna Stock Performance

Shares of Moderna stock opened at $142.77 on Friday. The firm has a market cap of $57.00 billion, a PE ratio of -17.87 and a beta of 0.91. The firm’s 50-day simple moving average is $75.62 and its 200-day simple moving average is $59.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $176.66.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted ($2.13) earnings per share. Equities analysts forecast that Moderna, Inc. will post -6.18 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.